KEGG   DRUG: Valoctocogene roxaparvovec
Entry
D12434                      Drug                                   
Name
Valoctocogene roxaparvovec (USAN/INN);
Valoctocogene roxaparvovec-rvox;
Roctavian (TN)
Product
Class
Blood modifier agent
 DG02016  Hemostatics
  DG02014  Blood coagulation accelerant
   DG02013  Blood coagulation factor
Remark
ATC code: B02BD15
Product: D12434<US>
Efficacy
Bleeding suppressant
  Disease
Hemophilia A [DS:H00219]
  Type
Gene therapy product
Comment
Treatment of hemophilia A
Target
F8* [HSA_VAR:2157v1] [HSA:2157] [KO:K03899]
  Pathway
hsa04610  Complement and coagulation cascades
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B02 ANTIHEMORRHAGICS
   B02B VITAMIN K AND OTHER HEMOSTATICS
    B02BD Blood coagulation factors
     B02BD15 Valoctocogene roxaparvovec
      D12434  Valoctocogene roxaparvovec (USAN/INN) <US>
Drug groups [BR:br08330]
 Blood modifier agent
  DG02016  Hemostatics
   DG02014  Blood coagulation accelerant
    DG02013  Blood coagulation factor
     D12434  Valoctocogene roxaparvovec
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Complement and coagulation
    F8* [HSA_VAR:2157v1]
     D12434  Valoctocogene roxaparvovec (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D12434
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12434
 Cellular and gene therapy products
  D12434
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12434
Other DBs
CAS: 1819334-78-5

» Japanese version   » Back

DBGET integrated database retrieval system